Serotonin syndrome with sertraline and indomethacin

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 468-470

  Coster, Suzan ^a   Visser, Mirjam H M ^a   Touw, Daan J ^a   Wirtz, Paul W ^a  

^a HAGA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; SERTRALINE; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; CASE REPORT; CEREBROSPINAL FLUID CULTURE; DEPRESSION; FEMALE; GLASGOW COMA SCALE; HEART ARREST; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; LETTER; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RESUSCITATION; SEROTONIN SYNDROME; CHEMICALLY INDUCED; DRUG INTERACTION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG INTERACTIONS; FEMALE; HUMANS; INDOMETHACIN; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 77955128768     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e6d846     Document Type: Letter

References (14)

1. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;325: 1112-1120.
2. Dunkley EJ, Isbister GK, Sibbritt D. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635-642.
3. Mills KC. Serotonin syndrome. A clinical update. Med Toxicol. 1997;13:763-783.
4. Kumar V, Wahlstrom JL, Rock DA, et al. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos. 2006;34:1966-1975.
5. Nakajima M, Inoue T, Shimada N, et al. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos. 1998;26:261-266.
6. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes mediating sertraline biotransformation: seeking attribution. J Clin Psychopharmacol. 1999;19:489-493.
7. Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos. 1999;27:763-766.
8. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33:262-270.
9. Grasmäder K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004;60:329-336.
10. Sprouse J, Clarke T, Reynolds L, et al. Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology. 1996;14: 225-231.
11. Duggan DE, Hogans AF, Kwan KC, et al. The metabolism of indomethacin in man. J Pharmacol Exp Ther. 1972;181: 563-575.
12. Ganetsky M, Bird SB, Liang IE. Acute myocardial infarction associated with serotonin syndrome. Ann Intern Med. 2006;144:782-783.
13. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med. 1991;324:641-648.
14. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry. 2006;51:923-929.